Navigation Links
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date:4/28/2011

volve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); uncertainties related to the regulatory process; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
6. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
7. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... 30, 2015 , ... This cutting edge standard making is a madatory tool ... peaks, the WAV-8 is the world’s first cuvette-shaped, solid-state filter that lets metrologists and ... range. Previous spectrophotometer calibration standards, such as those made from didymium glass were only ...
(Date:6/29/2015)... , June 29, 2015  AACC, a ... better health through laboratory medicine, is pleased to ... Clinical Chemistry , has increased to 7.9 ... This increase places Clinical Chemistry in ... reflects the significant influence of the research it ...
(Date:6/29/2015)... June 29, 2015   Veracyte, Inc . (Nasdaq: ... field of molecular cytology, today announced that it has ... Top Workplaces list for the second year in a ... solely on an annual survey of Bay Area-company employees. ... the degree to which Veracyte values our employees and ...
(Date:6/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... listed in the management information circular dated June 1, ... Meeting of Shareholders, held earlier today, June 26 ... 5 nominees proposed by management were elected as ... Company,s next Annual Meeting of Shareholders or until ...
Breaking Biology Technology:FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
... chemists from the University of Valencia (UV) has confirmed that ... remains at Lixus, in Morocco, was pine resin. The scientists ... could be fragments of material used for iron-working. In ... sealed amphora among the remains at Lixus, an ancient settlement ...
... , Feb. 5 Transgenomic, Inc. (OTC Bulletin Board: TBIO) ... will be presenting a corporate overview of the company at the 12th ... 11:30 a.m. EST on Tuesday, February 9, 2010 ... , About Transgenomic, Inc. , Transgenomic, Inc. ...
... and PALO ALTO, Calif. , Feb. 5 ... Philip Haworth , Ph.D., chief executive officer, will deliver a corporate ... Conference.  The conference will be held February 8-9, 2010 at ... will take place at 11:00 a.m. Eastern on Monday, ...
Cached Biology Technology:Chemical analyses uncover secrets of an ancient amphora 2Transgenomic Presents at 12th Annual BIO CEO & Investor Conference 2Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference 2Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference 3
(Date:6/23/2015)... Minn. , June 23, 2015   ... company that supports the entire spectrum of clinical ... iMedNet ™ , the company,s intuitive, ... been awarded a Silver 2015 Stevie® Award by ... Health Products & Services Website category.  The American ...
(Date:6/18/2015)... June 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market announces that its Wocket® ... on "Money on the Mark", scheduled to air on WABC ... June 20 th . The broadcast air- ... 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... -- A two-year study of college students at ... learn better and develop higher-level skills by participating ... teaching methods. Elsa Snchez and Richard Craig, ... surveyed students enrolled from 2003-2005 in their Plant ...
... -- We love it fresh, canned and frozen. It,s grown ... by the American Society of Horticultural Science, adds up to ... In other words, sweet corn is big business. Fresh ... July, with only ten percent of the annual volume marketed ...
... Two common dietary molecules found in legumes and ... of radiation, researchers from the University of Maryland ... human skin cells and a skin cancer-prone mouse ... damaging radiation found in sunlight, the team reported ...
Cached Biology News:Teamwork improves learning and career success 2How sweet is it? 2Antioxidants could provide all-purpose radiation protection 2Antioxidants could provide all-purpose radiation protection 3
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
UGT1A6 (D-20)...
... is the smallest electronic pressure controller available ... Parker configured this unit specifically for the ... Used in carrier gas flow control, microfluidic ... and hydro-dynamic focusing, the OEM-EPC offers external ...
... Thrust Slide is designed for heavy duty ... limited and substantial side-loading is present. Standard ... millions of trouble-free cycles even in high ... or recirculating ball bearings , Optional corrosion ...
Biology Products: